Non-invasive evaluation of portal-systemic shunting in man by D-sorbitol bioavailability.
Portal-systemic shunting is an important circulatory abnormality in patients with cirrhosis. This study explores the potential of the natural polyol D-sorbitol as test compound for non-invasive assessment of shunting. Ten normal subjects, 10 patients with cirrhosis and 12 cirrhotics with surgical portacaval shunts were studied after oral and intravenous administration of a 2 g dose of sorbitol. As measured by the H2 breath test, removal from the intestinal lumen was complete in both groups. Bioavailability of sorbitol, calculated as ratio of the areas under the plasma concentration/time curve after p.o. and i.v. administration, was zero in normal subjects, 0.29 +/- 0.15 in cirrhotic patients, and 0.38 +/- 0.11 in patients with portacaval shunts. Calculation of bioavailability on the basis of urinary outputs of sorbitol gave similar results. It is concluded that the bioavailability of sorbitol reflects portal-systemic shunting, although the relatively low figures suggest some degree of sorbitol metabolism by enterocytes.
Dipartimento di Biomedicina, Università di Torino, Italy.
A
A
Cavanna
G
G
Molino
M
M
Ballarè
M
M
Torchio
M
M
Fracchia
P
P
Avagnina
J
J
Bircher
D000328:Adult; D000368:Aged; D001682:Biological Availability; D005260:Female; D006801:Humans; D006975:Hypertension, Portal / Q000175:diagnosis / Q000378:metabolism*; D008099:Liver / Q000378:metabolism; D008103:Liver Cirrhosis / Q000150:complications / Q000175:diagnosis / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011170:Portasystemic Shunt, Surgical; D013012:Sorbitol / Q000378:metabolism*; D013997:Time Factors
D013012:Sorbitol